Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development Portfolio News / By Libby Nunan Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development Read More »
A2 Biotherapeutics Announces Findings from DENALI-1 Study of A2B395 Precision CAR T-Cell Therapy for Patients with Solid Tumors Expressing EGFR Portfolio News / By Libby Nunan A2 Biotherapeutics Announces Findings from DENALI-1 Study of A2B395 Precision CAR T-Cell Therapy for Patients with Solid Tumors Expressing EGFR Read More »
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Portfolio News / By Libby Nunan Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Read More »
InduPro Announces Publication in Nature Establishing Spatial Protein Proximity as a New Framework for Therapeutic Discovery Portfolio News / By Libby Nunan InduPro Announces Publication in Nature Establishing Spatial Protein Proximity as a New Framework for Therapeutic Discovery Read More »
Remix Therapeutics™ Appoints Nicole Sweeny as Chief Commercial Officer Portfolio News / By Libby Nunan Remix Therapeutics™ Appoints Nicole Sweeny as Chief Commercial Officer Read More »
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer Portfolio News / By Libby Nunan Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer Read More »
Kenai Therapeutics Appoints Mark Gergen to Board of Directors Portfolio News / By Libby Nunan Kenai Therapeutics Appoints Mark Gergen to Board of Directors Read More »
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001 Portfolio News / By Libby Nunan InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001 Read More »
Synthekine Appoints Veteran Biotech Leader Susan M. Molineaux, Ph.D. as Chief Executive Officer Portfolio News / By Libby Nunan Synthekine Appoints Veteran Biotech Leader Susan M. Molineaux, Ph.D. as Chief Executive Officer Read More »
Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia Portfolio News / By Libby Nunan Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia Read More »
